Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
The Phase 3 SYNCHRONIZE trials incorporate slower dose titration with the option to pause dosing during more severe symptoms, which should improve tolerability
Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., & Arcoraci, V
*Data not collected for US respondents What GLP-1 users say is changing: appetite, well-being, and daily habits Across the U.S
Clinical trials show semaglutide (Wegovy) produces average weight loss of approximately 15% over 68 weeks, liraglutide (Saxenda) around 810% over one year, and tirzepatide over 20% in some participants, all combined with lifestyle interventions
Over 2-3 months, patients typically observe increased energy and exercise recovery, early body composition changes, and improved skin quality
